Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

256 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz.
Focà E, Motta D, Borderi M, Gotti D, Albini L, Calabresi A, Izzo I, Bellagamba R, Narciso P, Sighinolfi L, Clò A, Gibellini D, Quiros-Roldan E, Brianese N, Cesana BM, Re MC, Torti C. Focà E, et al. Among authors: cesana bm. BMC Infect Dis. 2012 Feb 14;12:38. doi: 10.1186/1471-2334-12-38. BMC Infect Dis. 2012. PMID: 22333484 Free PMC article. Clinical Trial.
A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz.
Albini L, Cesana BM, Motta D, Focà E, Gotti D, Calabresi A, Izzo I, Bellagamba R, Fezza R, Narciso P, Sighinolfi L, Maggi P, Quiros-Roldan E, Manili L, Guaraldi G, Lapadula G, Torti C. Albini L, et al. Among authors: cesana bm. J Acquir Immune Defic Syndr. 2012 Jan 1;59(1):18-30. doi: 10.1097/QAI.0b013e31823a6124. J Acquir Immune Defic Syndr. 2012. PMID: 21992924 Clinical Trial.
Increase in standard cholesterol and large HDL particle subclasses in antiretroviral-naïve patients prescribed efavirenz compared to atazanavir/ritonavir.
Gotti D, Cesana BM, Albini L, Calabresi A, Izzo I, Focà E, Motta D, Bellagamba R, Fezza R, Narciso P, Sighinolfi L, Maggi P, Brianese N, Quiros-Roldan E, Guaraldi G, Torti C. Gotti D, et al. Among authors: cesana bm. HIV Clin Trials. 2012 Sep-Oct;13(5):245-55. doi: 10.1310/hct1305-245. HIV Clin Trials. 2012. PMID: 23134625
Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI.
Torti C, d'Arminio-Monforte A, Pozniak AL, Lapadula G, Cologni G, Antinori A, De Luca A, Mussini C, Castagna A, Cicconi P, Minoli L, Costantini A, Carosi G, Liang H, Cesana BM; MASTER, Chelsea & Westminster, ICONA, Modena and S. Raffaele HIV Cohorts. Torti C, et al. Among authors: cesana bm. BMC Infect Dis. 2011 Jan 25;11:23. doi: 10.1186/1471-2334-11-23. BMC Infect Dis. 2011. PMID: 21266068 Free PMC article. Clinical Trial.
Lessons learned and implications of early therapies for coronavirus disease in a territorial service centre in the Calabria region: a retrospective study.
Scaglione V, Rotundo S, Marascio N, De Marco C, Lionello R, Veneziano C, Berardelli L, Quirino A, Olivadese V, Serapide F, Tassone B, Morrone HL, Davoli C, La Gamba V, Bruni A, Cesana BM, Matera G, Russo A, Costanzo FS, Viglietto G, Trecarichi EM, Torti C; IDTM U. M. G. COVID-19 Group. Scaglione V, et al. Among authors: cesana bm. BMC Infect Dis. 2022 Oct 20;22(1):793. doi: 10.1186/s12879-022-07774-9. BMC Infect Dis. 2022. PMID: 36266619 Free PMC article.
Patterns of multi-drug resistant bacteria at first culture from patients admitted to a third level University hospital in Calabria from 2011 to 2014: implications for empirical therapy and infection control.
Reale M, Strazzulla A, Quirino A, Rizzo C, Marano V, Postorino MC, Mazzitelli M, Greco G, Pisani V, Costa C, Cesana BM, Liberto MC, Torti C, Focà A. Reale M, et al. Among authors: cesana bm. Infez Med. 2017 Jun 1;25(2):98-107. Infez Med. 2017. PMID: 28603227 Free article.
Prevalence of Antibiotic Resistance Over Time in a Third-Level University Hospital.
Scaglione V, Reale M, Davoli C, Mazzitelli M, Serapide F, Lionello R, La Gamba V, Fusco P, Bruni A, Procopio D, Garofalo E, Longhini F, Marascio N, Peronace C, Giancotti A, Gallo L, Matera G, Liberto MC, Cesana BM, Costa C, Trecarichi EM, Quirino A, Torti C. Scaglione V, et al. Among authors: cesana bm. Microb Drug Resist. 2022 Apr;28(4):425-435. doi: 10.1089/mdr.2021.0109. Epub 2021 Dec 15. Microb Drug Resist. 2022. PMID: 34910885 Free PMC article.
256 results